SC
LXRX icon

Sculptor Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Sculptor Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,500
Closed -$92K – 360
2017
Q3 		$92K Hold
7,500
– – ﹤0.01% 337
2017
Q2 		$123K Hold
7,500
– – ﹤0.01% 307
2017
Q1 		$108K Buy
+7,500
New +$111K ﹤0.01% 299

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Sculptor Capital's LXRX Position: Q4 2017 in Review

Sculptor Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2017, closing a stake of 7,500 shares — an estimated $92K sold.

Sculptor Capital first reported a position in LXRX in Q1 2017 and held it in 3 quarters. The position peaked at $123K in Q2 2017. 133 funds tracked by Wall St. Rank hold LXRX as of Q4 2017.

  • Sculptor Capital reported no remaining Lexicon Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Sculptor Capital sold 7,500 Lexicon Pharmaceuticals shares in Q4 2017, an estimated $92K.
  • Sculptor Capital first reported a position in Lexicon Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Sculptor Capital's Lexicon Pharmaceuticals position peaked at $123K in Q2 2017.
  • 133 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2017.

Based on Sculptor Capital's 13F filing for Q4 2017, filed 13 Feb 2018.